Xcout Intel
Naveris, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Naveris, Inc. among diagnostics companies — ranked by similarity to what Naveris, Inc. actually does, not by market-cap band.
Subscribe to see Naveris, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Naveris, Inc.
Naveris, Inc. is a biotechnology research and cancer detection company located in Waltham, Massachusetts. It specializes in developing advanced molecular diagnostic blood tests for HPV-associated cancers.
Naveris, Inc. at a glance
Naveris, Inc. is a diagnostics company headquartered in United States. Its most recent funding round raised $17.5M in June 2024. Xcout tracks 1 named person at Naveris, Inc., including John Hanna (President and Chief Executive Officer). Xcout recorded 1 job posting from Naveris, Inc. in the last 90 days.
Naveris, Inc. leadership
- John HannaPresident and Chief Executive Officer
Naveris, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $17.5M | — | |
| Series A | $19M | 1 named | |
| SEC Form D filing | $15.4M | — | |
| SEC Form D filing | $650,000 | — | |
| Series A | $3M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Naveris, Inc.
Xcout recorded 1 job posting from Naveris, Inc. in the last 90 days, from a hiring record Xcout has kept since July 2026.
The weekly hiring trend, the roles and locations behind it — see Naveris, Inc.'s hiring signals →
Recent Naveris, Inc. news
Top 12 Naveris, Inc. competitors
Ranked by semantic similarity — how close each company is to Naveris, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Mercy BioAnalytics, Inc. is a privately held biotechnology company founded in 2018 and headquartered in Waltham, Massachusetts. The company is dedicated to developing early diagnostics and detection technologies.
Medical Diagnostics, Biomedical Engineering, Liquid Biopsy
Nucleix is a liquid biopsy company headquartered in Rehovot, Israel. It aims to revolutionize cancer treatment through earlier disease detection, focusing on interventions that can bring the greatest impact.
Biotech
Precede Biosciences is a biotechnology company developing blood-based liquid-biopsy technologies for molecular profiling of cancer. Its tests are intended to support oncology research, precision treatment decisions, and pharmaceutical drug-development programs.
Biotechnology
Resolution Bioscience is a precision medicine company specializing in cancer diagnostics, DNA sequencing, and liquid biopsy, located in Bellevue, Washington.
Biotechnology
Nexosome Oncology Holdings, Inc. develops blood tests for early-stage cancer detection using patented extracellular vesicle proteomics and AI/ML biomarker discovery. The company serves patients and healthcare partners by providing highly accurate diagnostic tools.
Similar diagnostics company
Exosome Diagnostics, Inc. is a molecular diagnostics company located in Massachusetts, United States. The company specializes in developing biofluid-based liquid biopsy tests, such as the ExoDx Prostate test, for use in personalized medicine and oncology.
Diagnostics/Tools
Adela, Inc. is an epigenomics-focused biotechnology company headquartered in Foster City, California. The company is advancing breakthrough approaches for the early detection of multiple types of cancer through blood tests.
Biotechnology
Lucence is a precision oncology and health diagnostics company that provides ultrasensitive liquid biopsy tests, including cancer screening, treatment selection, and health risk assessment solutions. Using proprietary technologies like AmpliMARK, the company analyzes blood-based genetic material to detect cancer mutations, early-stage malignancies, and cardiovascular risks for patients and healthcare providers.
Similar diagnostics company
DELFI Diagnostics is a cancer detection company that utilizes artificial intelligence and whole genome fragmentation analysis to develop blood-based cancer screening tests, such as for lung cancer.
Healthcare & Cancer Diagnostics
Orchestra Health Technologies provides a platform combining proprietary software and care navigators to streamline the oncology diagnostic journey from biopsy to treatment decisions. The company serves cancer patients, oncologists, pathologists, and healthcare executives by coordinating pathology, molecular testing, and multi-disciplinary team workflows to accelerate precision medicine.
Biotech
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
Life Sciences
Pathwork Diagnostics developed molecular diagnostic tests for cancer, notably the Tissue of Origin test, which analyzes tumor gene-expression patterns to help identify the likely primary site of metastatic cancers when the origin is unknown. Its products served pathologists and oncologists managing patients with cancers of unknown primary.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Naveris, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Naveris, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →